This diagnostic image pair displays thoracic radiology findings in an 80-year-old male with Chronic Obstructive Pulmonary Disease (COPD). The left panel shows a frontal chest radiograph (X-ray) exhibiting hallmark signs of hyperinflation, including a widened anteroposterior diameter and flattened diaphragmatic domes. Both lung fields demonstrate sparse bronchovascular markings and increased lucency, indicative of diffuse emphysema. The right panel shows an axial CT scan of the thorax, further characterizing the pulmonary pathology. It reveals significant emphysematous destruction of the lung parenchyma with the presence of multiple bullae and areas of decreased attenuation. Additionally, subtle interstitial lesions are visible. The imaging illustrates the classic presentation of severe COPD, characterized by permanent enlargement of airspaces distal to the terminal bronchioles and associated structural changes to the chest wall often described as a barrel chest.

This diagnostic image displays a two-panel chest roentgenogram (X-ray) from a 65-year-old male, highlighting radiographic features of severe pulmonary emphysema and chronic obstructive pulmonary disease (COPD). Panel A presents a postero-anterior (PA) view, while Panel B provides a lateral view. Key findings include significant hyperinflation of the lung fields with marked flattening of the hemidiaphragms (indicated by white arrows), which loss their normal convex shape. In Panel A, a yellow arrow identifies areas of increased translucency and attenuation of vascular markings consistent with emphysematous parenchymal changes. A red arrow highlights the decreased zone of apposition, representing the diminished area where the diaphragm sits parallel to the inner rib cage. Panel B further illustrates the flattened diaphragmatic contour and an increased retrosternal clear space, reflecting an increased anterior-posterior thoracic diameter (barrel chest). These visual markers are clinically significant as they correlate with the mechanical basis of Hoover's sign, where the horizontal orientation of the diaphragm causes inward rib cage retraction during inspiration.

This diagnostic image is a posterior-anterior (PA) view chest X-ray illustrating radiological signs of chronic obstructive pulmonary disease (COPD), specifically emphysema. The lung fields exhibit diffuse hyperlucency and signs of hyperinflation, characterized by the flattening of the diaphragmatic domes bilaterally. Multiple white arrows point to areas of increased pulmonary lucency with a relative paucity of vascular markings, consistent with emphysematous parenchyma. There is no evidence of focal consolidation, pleural effusion, or pneumothorax. The cardiomediastinal silhouette and hilar contours appear within normal limits for this view. External medical devices are present, including cardiac monitoring leads and electrodes overlying the mid-thoracic region. The skeletal structures, including the ribs and clavicles, are intact. This image serves as a clinical example for medical students to recognize signs of obstructive lung disease and the visual presentation of pulmonary air-trapping on conventional radiography.

This diagnostic image is a posteroanterior (PA) chest X-ray demonstrating classic radiographic features of Chronic Obstructive Pulmonary Disease (COPD) and pulmonary emphysema. The lungs exhibit marked hyperinflation, characterized by an increased lung volume and a vertical orientation of the heart (narrowed cardiac silhouette). Key anatomical findings include significant bilateral flattening of the diaphragmatic domes and an increased number of visible anterior ribs (greater than seven), indicating air trapping. There is a notable pruning of the peripheral pulmonary vascular markings, with increased lucency in the lung fields suggestive of parenchymal destruction. The mediastinum appears relatively narrow, and the hilar structures are prominent. These findings are clinically significant as they illustrate the mechanical disadvantages placed on respiratory muscles due to chronic hyperinflation and decreased elastic recoil. The image serves as a textbook example for medical students and clinicians to identify obstructive lung disease manifestations on plain film radiography.

This diagnostic image consists of four high-resolution computed tomography (HRCT) axial sections of the lung parenchyma, illustrating the primary radiological patterns of emphysema in Chronic Obstructive Pulmonary Disease (COPD). Images A and B demonstrate centriacinar emphysema, characterized by small, focal areas of low attenuation (lucent airspaces) located in the center of the secondary pulmonary lobules, typically surrounding the central bronchovascular bundle. Image C displays panacinar emphysema, showing a more uniform and diffuse destruction of the entire acinus, resulting in generalized lung hyperlucency and attenuation of the pulmonary vasculature. Image D illustrates paraseptal emphysema (distal acinar emphysema), where focal lucent airspaces are distributed preferentially along the subpleural surfaces and interlobular septa, often demarcated by thin walls. Key educational concepts include the distinction between lobular distributions and the resulting architectural distortion and vascular attenuation associated with progressive alveolar wall destruction.

This diagnostic image is an axial non-contrast high-resolution computed tomography (HRCT) scan of the thorax at the level of the upper lobes. The image demonstrates bilateral, diffuse, and homogeneous areas of abnormally decreased lung attenuation (hyperlucency). These findings are characteristic of panacinar (panlobular) emphysema, where there is a uniform destruction of the pulmonary acinus. Key features include a simplified lung architecture with a notable paucity of pulmonary vascular markings throughout the affected parenchyma. Unlike centriacinar emphysema, which often shows focal areas of low attenuation, this presentation shows a generalized darkening of the lung fields without well-defined walls or cystic structures. No acute infiltrates, ground-glass opacities, or consolidations are present, which in a clinical context (such as COVID-19 screening) helps differentiate chronic obstructive pulmonary disease (COPD) from acute infectious processes. The image serves as a classic educational example of end-stage alveolar destruction and hyperinflation seen in severe emphysema.

This diagnostic image is an axial non-contrast chest CT scan at the level of the lower lobes, demonstrating characteristic features of panacinar emphysema. The lung parenchyma exhibits a diffuse, generalized decrease in attenuation (hypodensity) bilaterally, resulting in a significantly darker appearance than normal lung tissue. Structurally, there is extensive destruction of the alveolar walls, leading to the formation of numerous small, round, and irregularly shaped airspaces that give the parenchyma a coarse, 'swiss cheese' or porous texture. Unlike centriacinar emphysema which typically affects the upper lobes, these changes are distributed uniformly across the visible lung segments without regional predilection. Key landmarks include the central mediastinum with a visible heart and descending aorta, and the bilateral major fissures. There is a notable absence of peripheral ground-glass opacities or consolidations, distinguishing this chronic obstructive pulmonary disease (COPD) manifestation from acute infectious processes like COVID-19 bronchopneumonia.

A multi-panel clinical graphic illustrating the physical and diagnostic findings of Hoover's sign in a patient with airway obstruction. Panels A and B contain clinical photographs of a male patient's torso in a lateral recumbent position. Panel A (Inspiration) demonstrates a paradoxical inward retraction of the lower rib cage and intercostal spaces, a classic physical sign of diaphragmatic flattening often seen in severe COPD or emphysema. Panel B (Expiration) shows the relative expansion or outward movement of the same region. Panel C provides a spirometry data table showing an obstructive pattern: a reduced FEV1/FVC ratio (49%) and low FEF25-75% (31% of predicted). Panel D includes a flow-volume loop demonstrating characteristic expiratory flow limitation and a bar chart of lung volumes. The lung volume chart highlights significant hyperinflation and gas trapping, characterized by an elevated Residual Volume (RV) and Total Lung Capacity (TLC) compared to reference values. This composite image serves to correlate physical examination findings of abnormal chest wall dynamics with quantitative pulmonary function testing in obstructive lung disease.

Summary : This flowchart outlines the diagnostic process for COPD using pre- and post-bronchodilator spirometry, based on FEV1/FVC ratio thresholds. flowchart: # Nodes : • Start: "Measure Pre-Bronchodilator FEV1/FVC" (rectangle) • Decision: "FEV1/FVC ≥ 0.7" (rounded rectangle) • Outcome: "Not COPD" (rounded rectangle) • Note: "Measure Post-Bronchodilator FEV1/FVC if volume responder suspected e.g., low FEV1 or high symptoms" (rectangle) • Decision: "FEV1/FVC < 0.7" (rounded rectangle) • Next Step: "Measure Post-Bronchodilator FEV1/FVC" (rectangle) • Decision: "FEV1/FVC ≥ 0.7" (rounded rectangle) • Outcome: "Flow response: needs follow-up with repeat assessment" (rectangle) • Decision: "FEV1/FVC < 0.7" (rounded rectangle) • Outcome: "COPD confirmed" (rectangle) # Connectors : • From "Measure Pre-Bronchodilator FEV1/FVC" splits into two branches: – If "FEV1/FVC ≥ 0.7" → "Not COPD" → optional note about post-bronchodilator measurement if volume responder suspected. – If "FEV1/FVC < 0.7" → "Measure Post-Bronchodilator FEV1/FVC". • From "Measure Post-Bronchodilator FEV1/FVC" splits into: – If "FEV1/FVC ≥ 0.7" → "Flow response: needs follow-up with repeat assessment". – If "FEV1/FVC < 0.7" → "COPD confirmed". # Layout : • Top-down flow, starting with pre-bronchodilator measurement. • Two main branches based on initial FEV1/FVC ratio. • Right branch includes a second measurement and further decision nodes. • Left branch includes a conditional note for further testing if indicated. # Analysis : • The flowchart provides a clear, stepwise approach for diagnosing COPD using spirometry. • The key threshold for FEV1/FVC is 0.7, used both pre- and post-bronchodilator. • COPD is confirmed only if post-bronchodilator FEV1/FVC remains below 0.7. • If FEV1/FVC normalises after bronchodilator, further follow-up is recommended. • The chart allows for additional testing in cases where volume response is suspected, even if initial results are not diagnostic.

Summary : This figure compares spirometry traces between a normal individual and one with airflow obstruction, illustrating differences in forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), and the FEV1/FVC ratio. line plot: # Title & Axes : • Title: "A. Spirometry - Normal Trace" and "B. Spirometry - Airflow Obstruction" (Figure 2.5). • X-axis: "Time, seconds" (range: 0 to 6). • Y-axis: "Volume, liters" (range: 0 to 5). • Two panels: A (Normal Trace) and B (Airflow Obstruction). # Data Points : ## Panel A (Normal Trace) : • FEV1 = 4L (volume exhaled in first second). • FVC = 5L (total forced vital capacity). • FEV1/FVC = 0.8. • Curve rises steeply in first second, then plateaus near 5L. • FEV1 marked with a vertical dashed line at 1 second, horizontal at 4L. • FVC marked with a horizontal line at 5L. ## Panel B (Airflow Obstruction) : • FEV1 = 1.8L. • FVC = 3.2L. • FEV1/FVC = 0.56. • Curve rises slowly, plateaus near 3.2L. • FEV1 marked with a vertical dashed line at 1 second, horizontal at 1.8L. • FVC marked with a horizontal line at 3.2L. • "Obstructive" label at plateau. # Design Encodings : • FVC shown as a solid green horizontal line. • FEV1 shown as a dashed orange vertical and horizontal line at 1 second. • Volume-time curves: solid blue lines. • Beige annotation boxes with FEV1, FVC, and FEV1/FVC values. • Panel labels: "A" (left), "B" (right). # Distribution & Trends : • Panel A: Rapid rise in volume, high FEV1 and FVC, FEV1/FVC ratio within normal range. • Panel B: Slower rise, lower FEV1 and FVC, reduced FEV1/FVC ratio indicating obstruction. # Analysis : • The normal trace (Panel A) shows efficient, rapid exhalation with a high FEV1/FVC ratio (0.8). • The obstructive trace (Panel B) demonstrates impaired airflow, with a much lower FEV1 (1.8L) and FEV1/FVC ratio (0.56), consistent with obstructive lung disease. • The difference in curve shapes and ratios visually highlights the diagnostic utility of spirometry in distinguishing normal from obstructive patterns.

A clinical photograph of a printed arterial blood gas (ABG) analysis report. The document displays measured and calculated physiological values at a patient temperature of 37.0°C. Key measured values include a pH of 7.480, pCO2 of 22.3 mmHg, pO2 of 330.6 mmHg, and electrolyte levels (Na+ 143.4 mmol/L, K+ 3.28 mmol/L, Ca++ 1.03 mmol/L). Calculated values show a bicarbonate (HCO3-) level of 16.8 mmol/L and an oxygen saturation (SO2%) of 100.0%. This visual demonstrates a 'saturation gap' characteristic of certain toxicological conditions, such as methemoglobinemia, where the calculated oxygen saturation from the ABG appears normal (100%) despite the patient potentially experiencing clinical cyanosis and low peripheral pulse oximetry readings. The image is an educational tool for critical care, emergency medicine, and clinical toxicology, illustrating the interpretation of acid-base balance and oxygenation status.

Summary : This flowchart provides a structured approach for classifying the severity of COPD exacerbations, guiding clinicians through diagnosis, severity assessment, differential diagnosis, and etiology determination using specific clinical thresholds. flowchart: # Nodes : • Start (rectangle): "COPD Patient with Suspected Exacerbation" • Decision (split): "Confirm ECOPD Diagnosis and Episode Severity" (left branch) / "Consider Differential Diagnosis" (right branch) • Severity classification (rectangle, left branch): "Severity" with three sub-nodes: – Mild (default) – Moderate (meets at least three of five*) – Severe • Variable thresholds (rectangle, left branch): For each severity level, lists criteria: – Mild: Dyspnea VAS < 5, RR < 24 breaths/min, HR < 95 bpm, Resting SaO₂ ≥ 92%, CRP < 10 mg/L – Moderate: Dyspnea VAS ≥ 5, RR ≥ 24 breaths/min, HR ≥ 95 bpm, Resting SaO₂ < 92%, CRP ≥ 10 mg/L, ABG may show hypoxemia/hypercapnia but no acidosis – Severe: Same as moderate, plus ABG shows new onset/worsening hypercapnia and acidosis (PaCO₂ > 45 mmHg and pH < 7.35) • Etiology determination (rectangle, left branch): "Determine etiology: viral testing, sputum culture, other" • Differential diagnosis (rectangle, right branch): "Heart failure", "Pneumonia", "Pulmonary embolism" • Testing/treatment (rectangle, right branch): "Appropriate testing and treatment" # Connectors : • Main flow starts at "COPD Patient with Suspected Exacerbation" and splits into two branches. • Left branch flows downward through severity classification, variable thresholds, and etiology determination. • Right branch flows downward through differential diagnosis and appropriate testing/treatment. • Severity classification is hierarchical: mild, moderate, severe, each with its own criteria. • Moderate severity requires meeting at least three of five listed criteria. • Severe is defined by ABG findings in addition to moderate criteria. # Layout : • Horizontal split after initial node: left for ECOPD diagnosis/severity, right for differential diagnosis. • Left branch is vertically organized: severity → thresholds → etiology. • Right branch is vertically organized: differential diagnosis → testing/treatment. • Colour coding: yellow boxes for variable thresholds and differential diagnosis. # Analysis : • The flowchart provides a clear, stepwise method for classifying COPD exacerbation severity using objective clinical criteria (dyspnea VAS, RR, HR, SaO₂, CRP, ABG). • Moderate severity is defined by a combination of symptoms and lab findings, requiring at least three criteria. • Severe exacerbation is distinguished by the presence of acidosis on ABG. • The chart emphasizes the importance of considering alternative diagnoses (heart failure, pneumonia, pulmonary embolism) and appropriate testing. • The final step is to determine the etiology of the exacerbation using laboratory tests.